NZ298144A - Quinuclidine derivatives having muscarinic receptor antagonistic activity and medicaments therefrom - Google Patents

Quinuclidine derivatives having muscarinic receptor antagonistic activity and medicaments therefrom

Info

Publication number
NZ298144A
NZ298144A NZ298144A NZ29814495A NZ298144A NZ 298144 A NZ298144 A NZ 298144A NZ 298144 A NZ298144 A NZ 298144A NZ 29814495 A NZ29814495 A NZ 29814495A NZ 298144 A NZ298144 A NZ 298144A
Authority
NZ
New Zealand
Prior art keywords
group
mono
atom
tetrahydro
substituted
Prior art date
Application number
NZ298144A
Other languages
English (en)
Inventor
Makoto Takeuchi
Ryo Naito
Masahiko Hayakawa
Yoshinori Okamoto
Yasuhiro Yonetoku
Ken Ikeda
Isomura Yasuo
Original Assignee
Yamanouchi Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18194699&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ298144(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yamanouchi Pharma Co Ltd filed Critical Yamanouchi Pharma Co Ltd
Publication of NZ298144A publication Critical patent/NZ298144A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • C07D221/12—Phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K19/00—Liquid crystal materials
    • C09K19/04—Liquid crystal materials characterised by the chemical structure of the liquid crystal components, e.g. by a specific unit
    • C09K19/06—Non-steroidal liquid crystal compounds
    • C09K19/34—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring
    • C09K19/3441—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring having nitrogen as hetero atom
    • C09K19/3444—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring having nitrogen as hetero atom the heterocyclic ring being a six-membered aromatic ring containing one nitrogen atom, e.g. pyridine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Materials Engineering (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
  • Tea And Coffee (AREA)
NZ298144A 1994-12-28 1995-12-27 Quinuclidine derivatives having muscarinic receptor antagonistic activity and medicaments therefrom NZ298144A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP32704594 1994-12-28
PCT/JP1995/002713 WO1996020194A1 (en) 1994-12-28 1995-12-27 Novel quinuclidine derivatives and medicinal composition thereof

Publications (1)

Publication Number Publication Date
NZ298144A true NZ298144A (en) 1998-04-27

Family

ID=18194699

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ298144A NZ298144A (en) 1994-12-28 1995-12-27 Quinuclidine derivatives having muscarinic receptor antagonistic activity and medicaments therefrom

Country Status (24)

Country Link
US (2) US6017927A (enExample)
EP (1) EP0801067B1 (enExample)
JP (1) JP3014457B2 (enExample)
KR (1) KR100386487B1 (enExample)
CN (1) CN1045601C (enExample)
AT (1) ATE233761T1 (enExample)
AU (1) AU695616B2 (enExample)
CA (1) CA2208839C (enExample)
DE (2) DE69529844T2 (enExample)
DK (1) DK0801067T3 (enExample)
ES (1) ES2193208T3 (enExample)
FI (1) FI115631B (enExample)
FR (1) FR04C0032I2 (enExample)
HU (1) HU223778B1 (enExample)
LU (1) LU91133I9 (enExample)
MX (1) MX9704880A (enExample)
NL (1) NL300141I2 (enExample)
NO (4) NO2005012I1 (enExample)
NZ (1) NZ298144A (enExample)
PL (1) PL182344B1 (enExample)
PT (1) PT801067E (enExample)
RU (1) RU2143432C1 (enExample)
TW (1) TW305842B (enExample)
WO (1) WO1996020194A1 (enExample)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100137358A1 (en) * 1996-11-05 2010-06-03 Dr. Reddy's Laboratories Ltd. Solifenacin compositions
FR2772378B1 (fr) * 1997-12-12 2000-02-04 Synthelabo Derives d'imidazole, leur preparation et leur application en therapeutique
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US7214687B2 (en) 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
JP2001316670A (ja) * 2000-05-02 2001-11-16 Dainippon Ink & Chem Inc 液晶組成物
IL153707A0 (en) * 2000-06-27 2003-07-06 S A L V A T Lab Sa Carbamates derived from arylalkylamines
AU2002228015B2 (en) * 2000-12-22 2007-08-23 Almirall, S.A. Quinuclidine carbamate derivatives and their use as M3 antagonists
CA2433128C (en) 2000-12-28 2010-05-25 Almirall Prodesfarma Ag Novel quinuclidine derivatives and medicinal compositions containing the same
PT1405638E (pt) * 2001-07-10 2011-04-06 Astellas Pharma Inc Composição farmacêutica compreendendo 1-fenil-1,2,3,4 tetrahidroisoquinolino- 2-carboxilato de quinuclidin-3'-ilo para tratamento de cistite intersticial e/ou prostatite não bacteriana
EA006505B1 (ru) 2001-12-20 2005-12-29 Лабораториос С.А.Л.В.А.Т.,С.А. Производные карбамата 1-алкил-1-азониабицикло[2.2.2]октана и их применение в качестве антагонистов мускаринового рецептора
KR20050008795A (ko) * 2002-06-07 2005-01-21 야마노우치세이야쿠 가부시키가이샤 과활동 방광 치료제
ES2203327B1 (es) * 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2204295B1 (es) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
CN1668585A (zh) 2002-07-08 2005-09-14 兰贝克赛实验室有限公司 用作蝇蕈碱受体拮抗剂的3,6－二取代氮杂双环[3.1.0]己烷衍生物
AU2002368152A1 (en) 2002-07-31 2004-02-25 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo (3.1.0)hexane derivatives useful as muscarinic receptor antagonists
HK1079708A1 (zh) 2002-08-09 2006-04-13 Ranbaxy Laboratories, Ltd. 可用作毒蕈碱性受体拮抗剂的3，6-二取代氮杂二环[3．1．10]己烷衍生物
DE60231341D1 (de) 2002-08-23 2009-04-09 Ranbaxy Lab Ltd Fluor- und sulfonylaminohaltige, 3,6-disubstituierptorantagonisten
AU2003269380A1 (en) * 2002-10-29 2004-05-25 Pharmacia & Upjohn Company Llc Quinuclidinium derivatives as antimuscarinic agents
US7232835B2 (en) 2002-12-10 2007-06-19 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo derivatives as muscarinic receptor antagonists
ES2288641T3 (es) * 2002-12-20 2008-01-16 Dynogen Pharmaceuticals Inc. Metodo para tratar trastornos indoloros de la vejiga usando moduladores de canales del calcio de la subunidad alfa2-delta.
AU2002347553A1 (en) 2002-12-23 2004-07-14 Ranbaxy Laboratories Limited Flavaxate derivatives as muscarinic receptor antagonists
WO2004056767A1 (en) 2002-12-23 2004-07-08 Ranbaxy Laboratories Limited 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
US7488748B2 (en) 2003-01-28 2009-02-10 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
EP1721607A1 (en) * 2003-03-21 2006-11-15 Dynogen Pharmaceuticals, Inc. Methods for treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators
WO2004089898A1 (en) 2003-04-09 2004-10-21 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
US7560479B2 (en) 2003-04-10 2009-07-14 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
EA009059B1 (ru) 2003-04-10 2007-10-26 Рэнбакси Лабораториз Лимитед Замещенные производные азабициклогексана в качестве антагонистов мускаринового рецептора
BRPI0409302A (pt) 2003-04-11 2006-04-11 Ranbaxy Lab Ltd derivados azabiciclo como antagonistas de recetores muscarìnicos, método para sua preparação e composição farmacêutica contendo os mesmos
WO2004091597A2 (en) * 2003-04-15 2004-10-28 Pharmacia & Upjohn Company Llc Method of treating irritable bowel syndrome (ibs)
US20050175689A1 (en) * 2003-10-27 2005-08-11 Yamanouchi Pharmaceutical Co., Ltd. Coated fine particles containing drug for intrabuccally fast disintegrating tablet
EP1714965A4 (en) * 2004-02-09 2007-12-19 Astellas Pharma Inc COMPOSITION CONTAINING SOLIFENACINE SUCCINATE
WO2005077364A1 (ja) * 2004-02-18 2005-08-25 Yamanouchi Pharmaceutical Co., Ltd. ソリフェナシンの経皮投与製剤およびその経皮透過改善方法
ES2239546B1 (es) * 2004-03-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos esteres de quinuclidina cuaternizados.
EP1726304A4 (en) * 2004-03-16 2010-04-28 Astellas Pharma Inc COMPOSITION CONTAINING SOLIFENACIN
JPWO2005087231A1 (ja) * 2004-03-16 2008-01-24 アステラス製薬株式会社 ソリフェナシン含有組成物
AU2005226357B2 (en) * 2004-03-25 2010-07-01 Astellas Pharma Inc. Composition for solid pharmaceutical preparation of solifenacin or salt thereof
CN1934109B (zh) * 2004-03-25 2010-06-23 安斯泰来制药株式会社 用于固体制剂的索非那新或其盐的组合物
SE0400970D0 (sv) * 2004-04-14 2004-04-14 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
WO2006035280A1 (en) * 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited 3,4-dihydroisoquinoline compounds as muscrinic receptor antagonists for the treatment of respiratory, urinary and gastrointestinal diseases
WO2006035303A1 (en) * 2004-09-29 2006-04-06 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
CA2591817A1 (en) * 2004-12-22 2006-06-29 Memory Pharmaceuticals Corporation Nicotinic alpha-7 receptor ligands and preparation and uses thereof
WO2006070735A1 (ja) 2004-12-27 2006-07-06 Astellas Pharma Inc. ソリフェナシンまたはその塩の安定な粒子状医薬組成物
ES2387571T3 (es) * 2004-12-27 2012-09-26 Astellas Pharma Inc. Composición farmacéutica granulada estable de solifenacina o de su sal
EP1852117A4 (en) * 2005-02-25 2010-10-27 Astellas Pharma Inc PHARMACEUTICAL AGENT COMPRISING SOLIFENACIN
JP3701964B1 (ja) 2005-03-08 2005-10-05 アステラス製薬株式会社 キヌクリジン誘導体の新規な塩
WO2007007281A2 (en) * 2005-07-11 2007-01-18 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
US7815939B2 (en) * 2005-07-20 2010-10-19 Astellas Pharma Inc. Coated fine particles containing drug for intrabuccally fast disintegrating dosage forms
US20090221664A1 (en) 2005-10-19 2009-09-03 Abhijit Ray Pharmaceutical compositions of muscarinic receptor antagonists
EP1879867A2 (en) * 2005-12-21 2008-01-23 Teva Pharmaceutical Industries Ltd Intermediates for preparing solifenacin
CZ300699B6 (cs) * 2006-06-21 2009-07-22 Zentiva, A. S. Zpusob prípravy solifenacinu
EP2046751A4 (en) * 2006-07-19 2010-12-29 Reddys Lab Ltd Dr PROCESS FOR PRODUCING SOLIFENACIN AND ITS SALTS
ES2298049B1 (es) * 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
WO2008013851A2 (en) * 2006-07-24 2008-01-31 Teva Pharmaceutical Industries Ltd. Processes for preparing polymorphic forms of solifenacin succinate
WO2008019103A2 (en) * 2006-08-03 2008-02-14 Teva Pharmaceutical Industries Ltd Solifenacin base forms and preparation thereof
TW200825084A (en) * 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
CA2670365A1 (en) * 2006-11-22 2008-05-29 Medichem S.A. An improved process for the synthesis of solifenacin
CZ300692B6 (cs) * 2006-12-22 2009-07-15 Zentiva, A. S. Zpusob prípravy solifenacinu
CN101711248A (zh) * 2007-03-30 2010-05-19 医药化学公司 一种改进的素非那新合成工艺
EP2146693A2 (en) * 2007-04-11 2010-01-27 Dr. Reddy's Laboratories Ltd. Solifenacin compositions
WO2009011844A1 (en) * 2007-07-13 2009-01-22 Teva Pharmaceutical Industries Ltd. Processes for solifenacin preparation
WO2009013846A1 (ja) 2007-07-20 2009-01-29 Astellas Pharma Inc. 前立腺肥大に伴う下部尿路症状の改善用医薬組成物
EP2018850A1 (en) * 2007-07-24 2009-01-28 Ratiopharm GmbH Pharmaceutical composition comprising solifenacin or a pharmaceutically acceptable salt thereof
PL2216021T3 (pl) 2007-11-02 2013-03-29 Astellas Pharma Inc Kompozycja farmaceutyczna do leczenia zespołu pęcherza nadreaktywnego
JP2011505416A (ja) * 2007-12-04 2011-02-24 カディラ ヘルスケア リミティド 化学的及びキラル的に純粋なソリフェナシン塩基及びその塩を調製する方法
US8476297B2 (en) 2007-12-04 2013-07-02 Amgen Inc. TRP-M8 receptor ligands and their use in treatments
ITMI20080195A1 (it) 2008-02-08 2009-08-09 Dipharma Francis Srl Procedimento per la preparazione di solifenacin
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
MX344177B (es) 2008-03-27 2016-12-08 Chase Pharmaceuticals Corp Uso y composicion para tratar la demencia.
PL385265A1 (pl) * 2008-05-23 2009-12-07 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania solifenacyny i/lub jej soli o wysokiej czystości farmaceutycznej
PL385264A1 (pl) 2008-05-23 2009-12-07 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania enancjomerycznie czystej (S)-1-fenylo-1, 2, 3, 4-tetrahydroizochinoliny
SI3067353T1 (en) * 2008-07-29 2018-03-30 Krka, D.D., Novo Mesto Process for the preparation of solifenacin salts and their inclusion in pharmaceutical dosage forms
EP2181707A1 (en) 2008-11-04 2010-05-05 Astellas Ireland Co., Ltd. Combined use of an alpha-adrenergic receptor antagonist and an anti-muscarinic agent
DK2394648T3 (en) 2009-02-04 2016-09-26 Astellas Pharma Inc A pharmaceutical composition for oral administration
US8283470B2 (en) 2009-03-09 2012-10-09 Megafine Pharma(P) Ltd. Method for the preparation of solifenacin and intermediate thereof
WO2010113840A1 (ja) 2009-03-30 2010-10-07 アステラス製薬株式会社 ソリフェナシン非晶質体を含有した固形医薬組成物
WO2011048607A1 (en) * 2009-09-25 2011-04-28 Cadila Healthcare Limited Processes for the preparation of solifenacin or a salt thereof
PL234208B1 (pl) 2010-01-18 2020-01-31 Zakl Farmaceutyczne Polpharma Spolka Akcyjna Sposób wytwarzania bursztynianu solifenacyny
WO2011125763A1 (ja) 2010-03-31 2011-10-13 小野薬品工業株式会社 手足症候群の予防および／または治療剤
JP5812500B2 (ja) 2010-04-30 2015-11-17 メルク・シャープ・エンド・ドーム・コーポレイション 新規なβ３アドレナリン作動性受容体アゴニスト
ES2588008T3 (es) 2010-05-19 2016-10-28 Astellas Pharma Inc. Composición farmacéutica que contiene solifenacina
WO2012001481A1 (en) 2010-06-28 2012-01-05 Aurobindo Pharma Limited Novel process for the preparation of solifenacin succinate
US8765785B2 (en) 2010-07-05 2014-07-01 Crystal Pharma, S.A.U. Solifenacin salts
EP2638039A1 (de) 2010-11-11 2013-09-18 Hexal AG Kristallines solifenacin-succinat
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
MX348723B (es) 2011-05-10 2017-06-27 Theravida Inc Combinaciones de solifenacina y estimulantes salivales para el tratamiento de la vejiga hiperactiva.
EP2723734A1 (en) 2011-06-22 2014-04-30 Isochem Process for the preparation of solifenacin and salts thereof
KR101365849B1 (ko) 2012-03-28 2014-02-24 경동제약 주식회사 솔리페나신 또는 그의 염의 제조방법 및 이에 사용되는 신규 중간체
CN104411687A (zh) * 2012-07-02 2015-03-11 法尔玛赞公司 一种用于制备索非那新或其盐的方法
CN104602693A (zh) 2012-08-31 2015-05-06 安斯泰来制药株式会社 口服给药用药物组合物
HK1210947A1 (en) 2012-09-05 2016-05-13 Chase Pharmaceuticals Corporation Anticholinergic neuroprotective composition and methods
CN103787969B (zh) 2012-10-30 2016-07-06 上海京新生物医药有限公司 一种(1s)-1-苯基-3,4-二氢-2（1h）-异喹啉甲酸酯的制备方法
RU2661877C2 (ru) * 2012-12-06 2018-07-20 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета-2-адренергических рецепторов
EP2778167A1 (en) 2013-03-11 2014-09-17 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Stable pharmaceutical composition comprising amorphous solifenacin or its pharmaceutically acceptable salt
KR101823451B1 (ko) * 2013-07-13 2018-01-30 베이징 에프에스웰컴 테크놀로지 디벨롭먼트 컴퍼니 리미티드 퀴논계 화합물, 이의 광학 이성질체 및 이의 제조 방법과 의약 용도
CA2944714C (en) 2014-05-06 2023-05-16 Anthony G. Visco Methods of treating or preventing preterm labor
CN104592221A (zh) * 2015-01-26 2015-05-06 中山奕安泰医药科技有限公司 一种合成索非那新的工艺
KR20160146428A (ko) 2015-06-12 2016-12-21 한미정밀화학주식회사 솔리페나신 또는 그의 약학적으로 허용되는 염과 락토즈를 포함하는 안정한 무정형 솔리페나신 약학 조성물 및 그의 제조방법
KR102148414B1 (ko) 2017-05-15 2020-08-26 주식회사 서울제약 솔리페나신을 유효성분으로 하는 구강붕해필름
EP3724188B1 (en) * 2017-12-12 2023-06-07 Arkuda Therapeutics Progranulin modulators and methods of using the same
ES2992256T3 (es) 2018-05-08 2024-12-11 Nippon Shinyaku Co Ltd Compuestos de azabencimidazol y producto farmacéutico
AU2020290485A1 (en) * 2019-06-12 2021-12-02 Arkuda Therapeutics Progranulin modulators and methods of using the same
CN113200979A (zh) * 2021-04-13 2021-08-03 上海予君生物科技发展有限公司 一种琥珀酸索非那新的合成工艺

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2053451T3 (es) * 1986-01-07 1994-08-01 Beecham Group Plc Un procedimiento para la preparacion de un compuesto que tiene propiedades farmacologicas utiles.
IT1231238B (it) * 1987-09-21 1991-11-26 Angeli Inst Spa Derivati ammidinici
IT1228293B (it) * 1989-02-06 1991-06-07 Angeli Inst Spa Benzoderivati di composti eterociclici contenenti azoto.
IT1230881B (it) * 1989-06-20 1991-11-08 Angeli Inst Spa Derivati del r(-) 3-chinuclidinolo
GB9023023D0 (en) * 1990-10-23 1990-12-05 Barlow Richard B Pharmaceutical compositions
GB9202443D0 (en) * 1992-02-05 1992-03-18 Fujisawa Pharmaceutical Co A novel substituted-acetamide compound and a process for the preparation thereof
JPH076635A (ja) * 1993-06-18 1995-01-10 Sony Corp 信号伝送ケーブル
AU7545894A (en) * 1993-09-02 1995-03-22 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
JPH07258250A (ja) * 1994-03-25 1995-10-09 Yamanouchi Pharmaceut Co Ltd エステル誘導体
DE60308296T2 (de) * 2002-11-27 2007-09-06 Selmac S.R.L., Vigevano Vorrichtung zum Positionieren und Spannen geformter Teile und damit ausgerüstete Maschine

Also Published As

Publication number Publication date
NO318026B1 (no) 2005-01-24
KR100386487B1 (ko) 2003-09-26
KR987000303A (ko) 1998-03-30
HU223778B1 (hu) 2005-01-28
CN1171109A (zh) 1998-01-21
NO2005016I1 (no) 2005-08-29
NO973027L (no) 1997-08-28
NL300141I1 (nl) 2004-04-01
NO2005016I2 (no) 2008-02-11
DE69529844D1 (de) 2003-04-10
FI972775A7 (fi) 1997-08-22
JPH09508401A (ja) 1997-08-26
PT801067E (pt) 2003-07-31
ATE233761T1 (de) 2003-03-15
EP0801067B1 (en) 2003-03-05
WO1996020194A1 (en) 1996-07-04
RU2143432C1 (ru) 1999-12-27
LU91133I9 (en) 2018-08-01
NL300141I2 (nl) 2004-04-01
US6174896B1 (en) 2001-01-16
LU91133I2 (fr) 2005-03-29
NO2005012I1 (no) 2005-06-06
CN1045601C (zh) 1999-10-13
FI115631B (fi) 2005-06-15
US6017927A (en) 2000-01-25
FR04C0032I2 (fr) 2005-10-21
NO2017055I2 (no) 2017-11-06
DE69529844T2 (de) 2004-03-04
CA2208839C (en) 2006-01-31
DE122004000048I1 (de) 2005-04-21
FI972775A0 (fi) 1997-06-27
EP0801067A1 (en) 1997-10-15
ES2193208T3 (es) 2003-11-01
EP0801067A4 (en) 1998-03-11
TW305842B (enExample) 1997-05-21
PL321019A1 (en) 1997-11-24
PL182344B1 (pl) 2001-12-31
MX9704880A (es) 1997-10-31
AU695616B2 (en) 1998-08-20
CA2208839A1 (en) 1996-07-04
HUT77006A (hu) 1998-03-02
JP3014457B2 (ja) 2000-02-28
NO2017055I1 (no) 2017-11-06
FR04C0032I1 (enExample) 2005-02-11
NO973027D0 (no) 1997-06-27
DK0801067T3 (da) 2003-06-30
AU4355396A (en) 1996-07-19
DE122004000048I2 (de) 2006-02-02

Similar Documents

Publication Publication Date Title
EP0801067B1 (en) Novel quinuclidine derivatives and medicinal composition thereof
WO1997047601A1 (en) Fused heterocyclic compounds and medicinal uses thereof
US7078409B2 (en) Fused quinazoline derivatives useful as tyrosine kinase inhibitors
WO1995006635A1 (en) Carbamate derivative and medicine containing the same
EP0915094B1 (en) Morphinane derivatives and medicinal use thereof
EP0747355A1 (en) Novel carbamate derivative and medicinal composition containing the same
JPS6043342B2 (ja) イソキノリニウム化合物
EP0453197B1 (en) Amine derivatives
AU649836B2 (en) Derivatives of amide analogs of certain methano bridged quinolizines
US5968949A (en) Substituted hydroisoquinoline derivatives and their use as pharmaceuticals
KR100241662B1 (ko) 히드로이소퀴놀린 유도체
NO142838B (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive isokinolinderivater.
JP2003267977A (ja) キヌクリジン誘導体
KR19990077033A (ko) Cns 활성을 갖는 4,5-디히드로나프트[1,2-c]이속사졸 및그의 유도체
DK174564B1 (da) Benzazepinderivater, der er substitueret i 3-stillingen med en N-phenylalkyl-cycloalkyleniminogruppe, og lægemidler indeholdende sådanne forbindelser
WO1999038864A1 (en) Oxazole derivatives as serotonin-1a receptor agonists
JP2000109481A (ja) キヌクリジン誘導体含有医薬
EP0446921A2 (en) Optically active alkylene-dioxybenzene derivatives and their use in therapy
JPWO1996020194A1 (ja) 新規キヌクリジン誘導体及びその医薬組成物
WO1993003011A1 (fr) Derive d'uree
AU2006316706A1 (en) Isoquinoline and benzo[H]isoquinoline derivatives, preparation and therapeutic use thereof as antagonists of histamine H3 receptor
US4198420A (en) Spiro[dibenz(b,f)thiepin-piperidine]s
NZ231634A (en) Tetrahydrothiopyrano- and pentahydrothiepino-(2,3,-b)indole derivatives and pharmaceutical compositions
KR100824506B1 (ko) 퀴나졸리논 유도체
US4198418A (en) Spiro[dibenz(b,f)oxepin-piperidine]s

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
ASS Change of ownership

Owner name: ASTELLAS PHARMA INC., JP

Free format text: OLD OWNER(S): YAMANOUCHI PHARMACEUTICAL CO., LTD.

RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired